FREE SHIPPING ON ORDERS OVER $200 Now testing for heavy metals and endotoxins ≥98.5% purity Third-party HPLC tested COA on every batch Fast, discreet US shipping
Dihexa 10mg research peptide vial
Cognitive

Dihexa

N-hexanoic-Tyr-Ile-(6) aminohexanoic amide

An angiotensin-IV-derived peptide studied in synaptogenesis research.

$90

In stock · ships in 1–2 business days

  • ✓ 99.454% purity (tested)
  • ✓ HPLC + mass-spec tested
  • ✓ View batch COA
  • ✓ Discreet US shipping
synaptogenesisneuro research

Research Summary

Dihexa is an angiotensin IV-derived compound studied in preclinical research for hepatocyte-growth-factor/c-Met signaling and synaptogenesis models. For laboratory research use only.

Handling

Store the sealed lyophilized peptide at -20°C, protected from light and moisture. Let the vial reach room temperature before opening to limit condensation. Any further handling should follow your laboratory's own validated procedures, using appropriate protective equipment.

Research overview

Dihexa: what the research shows

Reviewed October 12, 2026 against PubMed and primary sources. For research context only, not medical advice.

What is Dihexa?

Dihexa is a synthetic, peptide-derived small molecule. Its structure is a hexanoyl group attached to tyrosine and isoleucine, capped at the C-terminus with a 6-aminohexanoic amide [1]. It was developed at Washington State University from angiotensin IV (AngIV), a fragment of the renin-angiotensin system that had been studied in rodent learning models for decades.

In a 2013 paper, the developing group described how it started from the three N-terminal residues of the AngIV analog Nle1-AngIV and modified the ends of that tripeptide to make it resistant to enzymatic breakdown and more able to cross biological barriers. The resulting compound, which the authors named dihexa, was reported to reverse scopolamine-induced deficits in the Morris water maze in rats and to increase synapse formation in hippocampal neuron cultures [2]. That paper later received an expression of concern from the journal (see below).

Dihexa is often discussed alongside the hepatocyte growth factor (HGF) and its receptor c-Met, because the developing group proposed that the compound acts by amplifying HGF signaling. For a longer background read, see our article Dihexa peptide research: synaptogenesis and neuroplasticity, and note the retraction information on this page, which postdates parts of that literature.

Dihexa molecular identity
StructureN-hexanoyl-L-tyrosyl-L-isoleucyl-(6)-aminohexanoic amide (Hexanoyl-Tyr-Ile-Ahx-NH2)
TypePeptide-derived small molecule (modified dipeptide) derived from angiotensin IV
Molecular formulaC27H44N4O5
Molecular weight504.7 g/mol
CAS number1401708-83-5 (PubChem synonym)
PubChem CID129010512
Other namesPNB-0408, N-hexanoic-Tyr-Ile-(6) aminohexanoic amide (PubChem synonyms)

Retractions in the core literature

Anyone evaluating Dihexa should know that key papers from the originating laboratory have been withdrawn or flagged by the journal that published them.

  • The 2014 mechanism paper was retracted. The study that linked Dihexa's reported effects to HGF/c-Met activation (Benoist et al., J Pharmacol Exp Ther 2014) received an expression of concern in 2021 and was retracted in 2025 at the editor's request [3] [4]. According to the retraction notice, an investigation by Washington State University found that figures and data in the article contained falsified and/or fabricated data, and two of the authors were found solely responsible [4].
  • Two related papers were also retracted. A 2012 paper on AngIV analogs as HGF/Met modifiers and a 2011 paper on HGF dimerization-domain mimics, from the same group and journal, were retracted in 2025 [5] [6].
  • The 2013 development paper carries an expression of concern. The paper describing Dihexa's design and early rat findings has had an expression of concern since 2021; it has not been retracted [2] [7].

As a result, the most widely repeated claims about Dihexa, including its high-affinity binding to HGF and the dependence of its effects on c-Met, rest partly on work that is no longer part of the valid scientific record. Independent replication is limited. The findings below are reported with that context.

Mechanisms studied

No mechanism for Dihexa has been confirmed in humans, and the central mechanistic paper has been retracted [4]. The hypotheses that remain in the literature are summarized here.

HGF/c-Met positive modulation (proposed)

The developing group proposed that Dihexa binds HGF and helps it form an active complex that phosphorylates the c-Met receptor at low HGF concentrations. Its 2015 reviews present this model in detail and describe c-Met signaling as influencing dendritic arborization and synapse formation [8] [9]. These reviews were written before the 2025 retractions and rely on data from the retracted papers.

Aminoglycoside hair-cell loss in zebrafish

In a 2015 study using the larval zebrafish lateral line, whose hair cells resemble mammalian inner-ear hair cells, Dihexa reduced hair-cell loss caused by the aminoglycosides neomycin and gentamicin. The protection was attenuated by an HGF antagonist and partially attenuated by inhibitors of Akt, TOR, and MEK. Dihexa did not reduce the amount of labeled gentamicin entering hair cells, which the authors took to mean that the effect was intracellular [10]. Two authors of this paper were also authors of the retracted work.

PI3K/AKT signaling

An independent group in China reported in 2021 that Dihexa activated the PI3K/AKT pathway in the brains of APP/PS1 transgenic mice, a model of amyloid pathology. A PI3K inhibitor, wortmannin, reversed the anti-inflammatory and anti-apoptotic changes the authors observed [11].

Areas of research

Rodent learning and memory models

In the 2021 APP/PS1 mouse study, the authors reported that Dihexa restored spatial learning in the Morris water maze, increased neuron counts on Nissl staining and synaptophysin (SYP) expression, reduced astrocyte and microglia activation, lowered IL-1 beta and TNF-alpha, and raised IL-10 [11]. This is one of the few published Dihexa studies from outside the originating laboratory.

A negative result in a neurotoxin model

Not every model has been positive. In a 2024 study in 40 male Wistar rats, Dihexa (named PNB-0408 in the paper) was given alongside the mitochondrial toxin 3-nitropropionic acid, which produces Huntington's-like motor and cognitive deficits. The authors reported that the compound did not protect the rats from the weight, motor, learning, or memory deficits caused by the toxin [12].

Peripheral nerve models

A 2021 study in Lewis rats with a transected and surgically repaired sciatic nerve tested mesenchymal stem cells, G-CSF, and Dihexa alone and in combinations. Motor function at 8 to 16 weeks improved significantly in the groups that received stem cells plus G-CSF or stem cells plus Dihexa [13]. The design does not isolate an effect of Dihexa alone, and one author was the senior author of the retracted papers.

Sensory hair cells

The zebrafish lateral-line work described above remains the main published study of Dihexa outside the central nervous system [10].

Open research questions

  • Whether the HGF/c-Met mechanism can be reproduced by independent laboratories now that the central paper has been retracted.
  • Pharmacokinetics, metabolism, and tissue distribution, which have little independent published characterization.
  • Long-term safety. HGF/c-Met signaling drives cell proliferation, migration, and survival in many tissues, so sustained activation is a reasonable concern that has not been studied for this compound.

State of the human evidence

There are no published clinical studies of Dihexa in PubMed. FDA states that it has not identified any human exposure data on drug products containing dihexa acetate by any route of administration [14].

Findings from cell, zebrafish, and rodent models should not be read as evidence of safety or benefit in people.

Regulatory status

  • Not FDA approved. Dihexa is not approved by the U.S. Food and Drug Administration for any use.
  • Compounding. FDA's page on bulk drug substances that may present significant safety risks (content current as of April 22, 2026) lists dihexa acetate among nominated substances that were later withdrawn. FDA's note states that it has not identified any human exposure data on drug products containing dihexa acetate administered via any route, and that it lacks important information about safety issues, including whether it would cause harm if administered to humans [14].
  • Checked 2026-10-12. Dihexa was not among the peptides reviewed at FDA's Pharmacy Compounding Advisory Committee meeting of July 23 and 24, 2026 [15].

Rejuvatide supplies Dihexa strictly as a research chemical for in vitro and laboratory use. It is not sold for human or veterinary use.

Testing and quality

Every Rejuvatide lot of Dihexa is tested by an independent laboratory for purity by HPLC and identity by mass spectrometry, and is also tested for endotoxin. The current certificates are shown below and in our COA library, where you can match the lot number on your vial to its report. Certificates are published exactly as the laboratory issued them.

Browse all cognitive and neuro research compounds, or see our FAQ for ordering and shipping questions.

Storage of lyophilized material

Dihexa ships as a lyophilized (freeze-dried) powder, which is stable at ambient temperature during transit. For long-term storage, keep sealed vials at -20°C, protected from light and moisture. Allow a vial to reach room temperature before opening to limit condensation. Handling of any prepared solutions should follow your laboratory's own validated procedures.

Certificate of Analysis

Independently tested by Freedom Diagnostics. This is the certificate for the current batch of Dihexa.

99.454%HPLC purity
Lot 800107-25051202Tested batch

Your browser cannot display the PDF inline. Open the Certificate of Analysis.

Dihexa FAQ

What is Dihexa?

Dihexa (PNB-0408) is a synthetic, angiotensin IV-derived small molecule, hexanoyl-Tyr-Ile-Ahx-NH2. It has been studied in rodent, cell, and zebrafish models in connection with the HGF/c-Met signaling system.

Has Dihexa research been retracted?

Yes, in part. The 2014 paper that linked Dihexa to HGF/c-Met activation was retracted in 2025 after a university investigation found falsified and/or fabricated data, and two related papers from the same group were also retracted. The 2013 development paper carries an expression of concern.

Is Dihexa FDA approved?

No. Dihexa is not FDA approved for any use. FDA states it has not identified any human exposure data for drug products containing dihexa acetate and lacks important safety information.

Has Dihexa been tested in humans?

No published clinical studies of Dihexa were found in PubMed as of October 2026. All published findings come from cell, zebrafish, and rodent models.

How is Rejuvatide Dihexa tested?

Each lot is tested by an independent laboratory for HPLC purity, mass-spec identity, and endotoxin. The certificates are published on the product page and in the COA library, matched to the lot number on the vial.

Is Dihexa for human use?

No. Rejuvatide sells Dihexa for laboratory research use only. It is not for human or veterinary use, and nothing on this site is medical advice.

References

  1. PubChem. Dihexa (N-(1-Oxohexyl)-L-tyrosyl-N-(6-amino-6-oxohexyl)-L-isoleucinamide), Compound CID 129010512. National Library of Medicine. Source
  2. McCoy AT, Benoist CC, Wright JW, et al. J Pharmacol Exp Ther. 2013;344(1):141-54. PubMed 23055539
  3. J Pharmacol Exp Ther. 2021;378(3):311. PubMed 34551987
  4. Benoist CC, Kawas LH, Zhu M, et al. J Pharmacol Exp Ther. 2025;392(4):103567. PubMed 40312093
  5. Kawas LH, McCoy AT, Yamamoto BJ, et al. J Pharmacol Exp Ther. 2025;392(4):103566. PubMed 40312092
  6. Kawas LH, Yamamoto BJ, Wright JW, et al. J Pharmacol Exp Ther. 2025;392(4):103568. PubMed 40312094
  7. J Pharmacol Exp Ther. 2021;378(3):313. PubMed 34551989
  8. Wright JW, Harding JW. J Alzheimers Dis. 2015;45(4):985-1000. PubMed 25649658
  9. Wright JW, Kawas LH, Harding JW. Prog Neurobiol. 2015;125:26-46. PubMed 25455861
  10. Uribe PM, Kawas LH, Harding JW, et al. Front Cell Neurosci. 2015;9:3. PubMed 25674052
  11. Sun X, Deng Y, Fu X, et al. Brain Sci. 2021;11(11). PubMed 34827486
  12. Wells RG, Azzam AF, Hiller AL, et al. J Huntingtons Dis. 2024;13(1):55-66. PubMed 38489193
  13. Weiss JB, Phillips CJ, Malin EW, et al. Ann Med Surg (Lond). 2021;71:102917. PubMed 34703584
  14. U.S. Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks (content current as of April 22, 2026). Source
  15. U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee meeting, July 23-24, 2026: questions for the committee. Source